Avatar photo

Dr Romero Gomez

  • Articles: 4
Videos & Slides: 4
Prof.-Manuel-Romero-Gomez

The Course of Liver Histology and Morbi-Mortality in NAFLD / NASH

Prof. Manuel Romero-Gomez discusses the course of liver histology and its impact on mortality and morbidity in patients with NAFLD and NASH. He clarifies how fibrosis determines the prognosis of NAFLD and is the main therapeutic target. The importance of steatosis is also discussed both at the early phase and advanced phase. Finally he reviews the association with HCC and CV risks.
Read More
Prof.-Manuel-Romero-Gomez

IMAGING BIOMARKERS IN NAFLD: COULD THEY AVOID LIVER BIOPSY?

The diagnosis of NASH is critically important for clinical trials and clinical practice. Today, the gold standard to diagnose NASH is a liver biopsy, as it’s the most complete diagnostic solution allowing clinicians to study key characteristics of the disease. But it has limitations. Liver biopsies require significant expertise both to perform but also to interpret the results. Biomarkers could play an important role and imaging biomarkers (transient elastography and shear-wave) plus MRI techniques allow assessment of liver damage in NAFLD with high diagnostic accuracy
Read More

Manuel Romero Gómez is Full-Professor of Medicine at the University of Seville, Spain. He is the Chief of the Digestive Diseases Department, Virgen del Rocío University Hospitals and Head of group for translational research in liver diseases at the Institute of Biomedicine of Seville and Spanish Network for Research in Digestive and liver diseases (CiberEHD). Leader of Sub-project 7 for the European Project FLIP (Fatty Liver Inhibition of Progression) and National leader of LITMUS project. Co-coordinator of European NAFLD Registry funded by EASL. Manuel Romero Gómez is a member of the Strategic for research Plan in Andalusia. He received the XI Award Javier Benjumea Puigcerver in investigation, Universidad de Sevilla-Focus Abengoa, 2014. He has published more than 340 peer-reviewed papers on gastrointestinal and liver diseases, directed more than 24 public-funded research projects and protected 10 different patents.

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES